HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.

Slides:



Advertisements
Similar presentations
Hepatitis C in Retrospect David Gladders Portsmouth City Council.
Advertisements

Hepatitis C Treatment in Corrections: New Medicine, New Challenges
African Americans and Hepatitis C
Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections.
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
Liver Disease and Thalassaemia George Constantinou.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a versus Interferon alfa-2a Phase 3 Treatment Naïve, Chronic HCV Zeuzem S, et al. N Engl J.
Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Manns.
Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
Hepatitis C Disease & Treatment.
Hepatitis C testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Hepatitis C? Hepatitis C is a contagious.
Brittany Winfield. Hepatitis C is transferred through contact with infected blood including sexual, breaks in skin when in contact with blood, and infected.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Topic : Hepatitis C. Hepatitis C is an infectious disease of liver which is caused by Hepatitis C virus. It causes the inflammation of liver. Initial.
Hepatitis C What you need to know. What is Hepatitis C?  Hepatitis C is the most common chronic blood borne illness in the U.S, approximately 3.2 million.
Hepatitis C.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
Modelled impact of antiviral therapy on the future burden of HCV disease in Scotland Testing/Treatment/Care Working Group, 11 th Sept 2007.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
National policy on Hepatitis B at the Workplace
Wyoming Department of Health Communicable Diseases
Hepatitis B.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Hepatitis B - Sexually Transmitted Infection - Infects the liver and causes inflammation - About 1/3 people in the world have Hepatitis B - Can lead to.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
By: Megan Agren, Keriann Pfleger, and Crystal Forkey.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Phase 3 Treatment Naïve, Chronic HCV Muir AJ,
Hepatitis C A Growing Problem of Pakistan. Group Members Zoya Imran Mariam Archer Nawal Nawaz Sidra Tul Muntaha.
Hepatitis C in Egypt Seif Tamer Ahmed Naser. What is it? Liver disease caused by Hepatitis C virus Can range from mild illness lasting a few weeks to.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Inflammation of the Liver Past | Present | Future
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Treating Hep C with Novel Agents
Boceprevir in Treatment Naive SPRINT-2
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Volume 155, Issue 5, Pages e2 (November 2018)
Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection
Fig. 6.9.
Phase 3 Treatment-Naïve and Treatment-Experienced
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Presentation transcript:

HEPATITIS C Kimberly Klatt

CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases caused by HCV 1

GLOBAL PREVALENCE AND RISK FACTORS  2 %-3% of global population has been infected  Higher prevalence in underdeveloped countries  Egypt has highest reported prevalence (>10%)  Higher risk if exposed to infected blood  Travelers receiving blood transfusions or other medical treatment  Tattoo or piercing parlors  Anyone working in the medical field

DISEASE HOSTS AND TRANSMISSION  Causes Hepatitis C infection  Cirrhosis  Liver failure  Humans and chimpanzees can carry and spread the disease  Bloodborne virus

TREATMENTS  Pegylated interferon and ribavirin: weeks  Sustained virologic response (SVR)  50% of treated patients  2011: Telaprevir and boceprevir added to treatment regimen  Treatment most effective if diagnosed within 1 year of infection  Difficult to diagnose – asymptomatic or mildly symptomatic  Currently no vaccine

REFERENCES "Hepatitis C." MedlinePlus. National Institutes of Health, 26 Nov Web. 4 Dec Hepatitis Central,. "Are there different types of Hepatitis C?." Hepatitis Central. Hepatitis Central, n.d. Web. 4 Dec Holtzman, Deborah. "Chapter 3: Infectious Diseases Related to Travel." Centers for Disease Control and Prevention. CDC, 01 Aug Web. 4 Dec Nwakamma, Blessing. "Hepatitis C Virus.". Austin Community College. Web. 4 Dec